Evidence map›Paper›PMID 36657529›Full record

ArticleGastroenterology2023

Injectable, Drug-Eluting Nanocrystals Prevent Fibrosis and Stricture Formation In Vivo.

Ling Li, Rachel L Shapiro, Min Kyung Joo, Aditya Josyula, Henry T Hsueh, Olaya Brewer Gutierrez, Gilad Halpert, Venkata Akshintala, Haiming Chen, Samuel Curtis and 11 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Challenges in IBD Research 2024: Novel Technologies.Inflammatory bowel diseases · 2024
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Ling LiDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Rachel L ShapiroCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Min Kyung JooCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Aditya JosyulaCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Henry T HsuehCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Olaya Brewer GutierrezDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Gilad HalpertCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Venkata AkshintalaDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Haiming ChenDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Samuel CurtisCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Marina BetterCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Charlotte DavisonCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Haijie HuDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Jose Antonio Navarro AlmarioDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Steven N SteinwayDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Kelton HuntDepartment of Chemistry and Biochemistry, Utah Tech University, St George, Utah.
Rico E Del SestoDepartment of Chemistry and Biochemistry, Utah Tech University, St George, Utah.
Jessica IzziDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, Maryland.
Kevan J SalimianDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Laura M EnsignCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: lensign@jhmi.edu.
Florin M SelaruDivision of Gastroenterology and Hepatology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland; The Institute for Nanobiotechnology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: fselaru1@jhmi.edu.
Johns Hopkins University · USUtah Tech University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI JEFFREY MUMM · 1985 to 2026
$22.1M
Tissue pharmacology imaging and modelingU19AI113127 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BUMPUS, NAMANDJE N · 2014 to 2018
$20.7M
Tissue biopsying with wireless microgrippers within gastrointestinal tractR01EB017742 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI David H Gracias, Florin Selaru · 2014 to 2026
$6.6M
Pharmacology and Molecular Sciences Training Program: Enhancing Inclusivity Through Universal Design for Learning in Graduate CoursesT32GM135083 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Caren L. Freel Meyers · 2020 to 2026
$3.3M
(PQC-1) Driver Events In IBD-Associated Neoplastic ProgressionR01CA190040 · NCI · JOHNS HOPKINS UNIVERSITY · PI MELTZER, STEPHEN J, SELARU, FLORIN · 2014 to 2017
$2.5M
Mucus-Penetrating Nanoparticle Containing Enemas for Ulcerative ColitisR01DK107806 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ENSIGN, LAURA, HANES, JUSTIN S. · 2016 to 2019
$1.5M
NCI NIH HHS R01 CA190040NEI NIH HHS P30 EY001765NIAID NIH HHS U19 AI113127NIBIB NIH HHS R01 EB017742NIDDK NIH HHS R01 DK107806NIGMS NIH HHS T32 GM135083
6 · The paper itself

Abstract

BACKGROUND &

aimsTissue fibrosis results from uncontrolled healing responses leading to excessive mesenchymal cell activation and collagen and other extracellular matrix deposition. In the gastrointestinal tract, fibrosis leads to narrowing of the lumen and stricture formation. A drug treatment to prevent fibrosis and strictures in the gastrointestinal tract would be transformational for patient care. We aimed to develop a stricture treatment with the following characteristics and components: a small molecule with strong antifibrotic effects that is delivered locally at the site of the stricture to ensure correct lesional targeting while protecting the systemic circulation, and that is formulated with sustained-release properties to act throughout the wound healing processes.

methodsA high-throughput drug screening was performed to identify small molecules with antifibrotic properties. Next, we formulated an antifibrotic small molecule for sustained release and tested its antifibrotic potential in 3 animal models of fibrosis.

resultsSulconazole, a US Food and Drug Administration-approved drug for fungal infections, was found to have strong antifibrotic properties. Sulconazole was formulated as sulconazole nanocrystals for sustained release. We found that sulconazole nanocrystals provided superior or equivalent fibrosis prevention with less frequent dosing in mouse models of skin and intestinal tissue fibrosis. In a patient-like swine model of bowel stricture, a single injection of sulconazole nanocrystals prevented stricture formation.

conclusionsThe current data lay the foundation for further studies to improve the management of a range of diseases and conditions characterized by tissue fibrosis.

Indexed as

CollagenExtracellular MatrixAnimalsConstriction, PathologicDelayed-Action PreparationsFibrosisMiceSwineCollagenDelayed-Action PreparationsFibrosisNanocrystalStrictureSulconazoleTherapies

Identifiers

PMID36657529
PMCPMC10151160
OpenAlexW4316655751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.